ACE-031

Price and cost-per-mg comparison

ACE-031 is a soluble decoy receptor fusion protein consisting of the extracellular domain of activin type IIA receptor (ActRIIA) linked to a human IgG1 Fc region, developed by Acceleron Pharma to bind and sequester myostatin, activin, and related TGF-beta superfamily ligands that negatively regulate muscle mass, with the goal of promoting muscle growth in severe wasting conditions including Duchenne muscular dystrophy. By competitively binding circulating myostatin and related ligands, ACE-031 reduces signaling through the Smad2/3 pathway that suppresses muscle satellite cell activation and protein synthesis; in preclinical models of myopathy, blockade of ActRIIA signaling produced significant increases in lean mass, supporting its evaluation in Phase 2 human trials. A Phase 2 randomized placebo-controlled trial in ambulatory boys with Duchenne muscular dystrophy demonstrated significant increases in lean body mass; however, the trial was halted early due to vascular-related adverse events including epistaxis and telangiectasias, attributed to off-target inhibition of angiogenic TGF-beta family ligands, and the Acceleron clinical program was subsequently discontinued. ACE-031 has no FDA approval and is not approved for any indication; commercial development was halted due to the adverse event signal identified in the clinical trial; it is not commercially available, and the vascular safety concern inherent to pan-ActRIIA ligand inhibition represents an unresolved risk that precludes its extrapolation to general performance or muscle enhancement applications.

13 listings · 12 vendors · updated 28 Sept 2026 · how prices are computed · educational only, not medical advice